Low Density Lipoprotein (LDL) News and Research

RSS

Chemicals in non-stick cookware elevates cholesterol level among children: Report

Children and teens with higher blood levels of chemicals used in the production of non-stick cookware and waterproof fabrics appear more likely to have elevated total and LDL cholesterol levels, according to a report in the September issue of Archives of Pediatrics & Adolescent Medicine, one of the JAMA/Archives journals.

7 Sep 2010

CaPre drug candidate shows promising result on CRP level reduction

Acasti Pharma Inc., a subsidiary of Neptune Technologies & Bioressources Inc. reports significant results on the effects of its anti-dyslipidemic investigational drug candidate CaPre on C-reactive protein (CRP) levels, a biomarker of CardioVascular Disease risk (CVD) and associated with diabetes and obesity.

3 Sep 2010

Mipomersen Phase 3 trial in heFH meets primary, secondary and tertiary endpoints

Genzyme Corp. and Isis Pharmaceuticals Inc. announced that data from the phase 3 study of mipomersen in patients with heterozygous familial hypercholesterolemia (heFH) were presented today at the European Society of Cardiology's Congress 2010 in Stockholm, Sweden. The study met its primary endpoint with a 28 percent reduction in LDL-cholesterol, compared with an increase of 5 percent for placebo (p<0.001). The trial also met all of its secondary and tertiary endpoints.

2 Sep 2010

DASH eating plan reduces long-term risk of heart attack among African-Americans: Study

The DASH eating plan, known to reduce blood pressure and bad cholesterol, also reduces the 10-year risk of heart attack, especially among African-Americans, according to research reported in Circulation: Cardiovascular Quality and Outcomes, an American Heart Association journal.

2 Sep 2010

DASH eating plan reduces heart disease risk in African Americans: Study

A new study suggests yet another reason for Americans to abandon their current fatty diets in favor of one rich in fruits and vegetables and low in saturated fat. Choosing these healthier options appears to significantly reduce the long-term risk of heart disease in patients with mildly elevated blood pressure, particularly African Americans.

2 Sep 2010

Study determines dose-specific patterns associated with generic statin switching

Research conducted in the Netherlands has highlighted the need for care when switching patients under treatment for high cholesterol from branded to generic drug families. The study shows that much of the switching can result in patients inadvertently receiving non-equivalent doses, potentially leading to an increased risk of downstream heart disease and stroke.

31 Aug 2010

Study shows statin therapy not associated with cancer

In the largest and most reliable study of its type, the University of Oxford (UK) and the University of Sydney (Australia) have demonstrated that statin therapy is not a cause of increased cancer rates and deaths. The conclusions of this study will reassure the millions of people worldwide who are taking statins to lower cholesterol levels, and clarifies earlier research that had raised concerns of a causal link.

31 Aug 2010

Study finds BMI, thrombogenic factor increases cardiovascular risk

Although having a high body mass index (BMI) is a known risk factor for cardiovascular disease, researchers are only beginning to understand how BMI affects the physiological processes involved in the development of the disease. Now, a study of a subset of women in the Kronos Early Estrogen Prevention Study (KEEPS), suggests that as BMI increases, so do platelet reactivity and thrombogenic microvesicles and activated protein C in the blood-all of which contribute to the formation of atherothrombosis and associated cardiovascular events.

30 Aug 2010

Spoonful of black rice bran contains more health promoting anthocyanin antioxidants than blueberries

Health conscious consumers who hesitate at the price of fresh blueberries and blackberries, fruits renowned for high levels of healthful antioxidants, now have an economical alternative, scientists reported here today at the 240th National Meeting of the American Chemical Society. It is black rice, one variety of which got the moniker "Forbidden Rice" in ancient China because nobles commandeered every grain for themselves and forbade the common people from eating it.

27 Aug 2010

Atherotech Diagnostics to exhibit VAP Cholesterol Test at NLA Summer 2010 Clinical Update

Atherotech Diagnostics Lab will exhibit its VAP Cholesterol Test in booth 105 at the National Lipid Association (NLA) Summer 2010 Clinical Lipid Update.

26 Aug 2010

Celera granted US patent on LPA gene variant's association with increased risk for myocardial infarction

Celera Corporation today announced that the United States Patent and Trademark Office has issued United States Patent 7,781,168 relating to methods of determining heart attack risk by detecting the Ile4399Met genetic polymorphism in the protease-like domain of LPA.

25 Aug 2010

Statin therapy reduces cardiovascular disease risk in patients with high sensitivity C-reactive protein

People at intermediate risk of cardiovascular disease who have high levels of high sensitivity C-reactive protein (hsCRP), a blood marker for inflammation, could benefit from cholesterol-lowering therapy even if their cholesterol is already at desirable levels.

25 Aug 2010

Impax confirms initiation of challenge of patents listed by MSP Singapore for VYTORIN

Impax Laboratories, Inc. today confirms that it has initiated a challenge of patents listed by MSP Singapore Co. LLC in connection with VYTORIN® (ezetimibe/simvastatin), 10 mg/80 mg.

21 Aug 2010

Statin drugs can neutralise heart disease dangers of fatty food: Study

Fast food outlets could provide statin drugs free of charge so that customers can neutralise the heart disease dangers of fatty food, researchers at Imperial College London suggest in a new study published this week.Statins reduce the amount of unhealthy "LDL" cholesterol in the blood. A wealth of trial data has proven them to be highly effective at lowering a person's heart attack risk.

13 Aug 2010

Fast food outlets can provide statin drugs to help customers neutralise heart disease: Researchers

12 Aug 2010

Amarin completes enrollment in AMR101 Phase 3 MARINE clinical trial

Amarin Corporation plc, a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that its MARINE trial, a Phase 3 clinical trial of AMR101, has completed patient enrollment and randomization into the treatment phase of this trial. The Company indicated that top line results from this trial are expected early in 2011, towards the early part of the range of guidance provided previously.

10 Aug 2010

Isis second-quarter pro forma net operating loss increases to $15.5 million

Isis Pharmaceuticals, Inc. today announced its financial results for the quarter ended June 30, 2010. The Company finished the second quarter of 2010 with a pro forma net operating loss (NOL) of $15.5 million and $17.1 million for the three and six months ended June 30, 2010, respectively, compared to a pro forma net operating loss of $1.3 million and pro forma net operating income of $798,000 for the same periods of 2009.

9 Aug 2010

Alnylam publishes research findings of Sort1 gene role in cardiovascular disease development

Alnylam Pharmaceuticals, Inc. a leading RNAi therapeutics company, announced today the publication of new research findings in the journal Nature describing the discovery and validation of the role of the gene Sort1 in the development of cardiovascular disease, including myocardial infarction (MI). This work was done with collaborators at University of Pennsylvania (UPenn) School of Medicine, Massachusetts General Hospital (MGH), and the Broad Institute. The collaborative effort combined genome-wide association studies (GWAS) and RNAi technology to identify and validate novel genes as targets for new therapies for heart disease.

6 Aug 2010

Genzyme, Isis announce results of two mipomersen phase 3 studies

Genzyme Corp. and Isis Pharmaceuticals Inc. today announced results of two phase 3 studies of mipomersen in patients who had high cholesterol levels while on maximally tolerated lipid-lowering therapy. In the study of patients with severe hypercholesterolemia, mipomersen reduced LDL-C, the primary endpoint, by 36 percent compared with a 13 percent increase for placebo.

5 Aug 2010

SORT1 pathway holds promise as new target for therapeutic intervention for LDL cholesterol reduction

The true power of genomic research lies in its ability to help scientists understand biological processes, particularly those that - when altered - can lead to disease. This power is demonstrated dramatically in a pair of papers published today in the journal Nature. In the first, a global team of researchers describes 95 different variations across the genome that contribute in different degrees to alterations in blood cholesterol and triglyceride levels in multiple human populations. In the second report, close examination of just one of these common variants not only reveals the involvement of an unexpected genetic pathway in lipid metabolism but also provides a blueprint for using genomic findings to unravel biological connections between lipid levels and coronary heart disease.

5 Aug 2010

Low Density Lipoprotein (LDL) News and Research

Chemicals in non-stick cookware elevates cholesterol level among children: Report

CaPre drug candidate shows promising result on CRP level reduction

Mipomersen Phase 3 trial in heFH meets primary, secondary and tertiary endpoints

DASH eating plan reduces long-term risk of heart attack among African-Americans: Study

DASH eating plan reduces heart disease risk in African Americans: Study

Study determines dose-specific patterns associated with generic statin switching

Study shows statin therapy not associated with cancer

Study finds BMI, thrombogenic factor increases cardiovascular risk

Spoonful of black rice bran contains more health promoting anthocyanin antioxidants than blueberries

Atherotech Diagnostics to exhibit VAP Cholesterol Test at NLA Summer 2010 Clinical Update

Celera granted US patent on LPA gene variant's association with increased risk for myocardial infarction

Statin therapy reduces cardiovascular disease risk in patients with high sensitivity C-reactive protein

Impax confirms initiation of challenge of patents listed by MSP Singapore for VYTORIN

Statin drugs can neutralise heart disease dangers of fatty food: Study

Fast food outlets can provide statin drugs to help customers neutralise heart disease: Researchers

Amarin completes enrollment in AMR101 Phase 3 MARINE clinical trial

Isis second-quarter pro forma net operating loss increases to $15.5 million

Alnylam publishes research findings of Sort1 gene role in cardiovascular disease development

Genzyme, Isis announce results of two mipomersen phase 3 studies

SORT1 pathway holds promise as new target for therapeutic intervention for LDL cholesterol reduction

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News